Use of Herbal Products and Potential Interactions in Patients With Cardiovascular Diseases

Journal of the American College of Cardiology

Volumn 55, Issue 6, 2010, Pages 515-525

  Tachjian, Ara ^a   Maria, Viqar ^a   Jahangir, Arshad ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

cardiovascular agents; complementary therapies; drug approval; herb drug interaction; herbal medicine

Indexed keywords

ACONITUM EXTRACT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARISTOLOCHIC ACID; CALCIUM CHANNEL BLOCKING AGENT; CIMICIFUGA RACEMOSA EXTRACT; CRATAEGUS EXTRACT; CYCLOSPORIN; CYTOCHROME P450 3A4; DIGOXIN; ECHINACEA EXTRACT; EPHEDRA EXTRACT; ESTROGEN; ETHINYLESTRADIOL; GARLIC EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; GLYCYRRHIZA EXTRACT; GRAPEFRUIT EXTRACT; GYNURA EXTRACT; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; IMMUNOSUPPRESSIVE AGENT; INDINAVIR; SABAL EXTRACT; SALVIA MILTIORRHIZA EXTRACT; TETRANDRINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; YOHIMBINE;

ACONITE; AEROBIC METABOLISM; BRAIN HEMORRHAGE; BREAST CANCER; CANCER RISK; CARDIAC GRAFT REJECTION; CARDIOVASCULAR DISEASE; CIMICIFUGA RACEMOSA; CLINICAL TRIAL; COMA; CRATAEGUS; DEMENTIA; DIET SUPPLEMENTATION; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG LABELING; DRUG MARKETING; DRUG METABOLISM; DRUG SAFETY; ECHINACEA; FOOD AND DRUG ADMINISTRATION; GARLIC; GINKGO BILOBA; GINSENG; GLYCYRRHIZA; GOVERNMENT REGULATION; GRAFT REJECTION; GRAPEFRUIT JUICE; HEALTH EDUCATION; HEART ARRHYTHMIA; HEART INFARCTION; HEMATOMA; HEMOSTASIS; HERB DRUG INTERACTION; HERBAL MEDICINE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERICUM PERFORATUM; HYPHEMA; INOTROPISM; INTERNET; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; LACTATION; LIVER TOXICITY; MEDLINE; MENOPAUSE; MOTHERWORT; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTHROMBIN TIME; QUALITY CONTROL; REVIEW; RHINOVIRUS INFECTION; SABAL; SALVIA MILTIORRHIZA; SEIZURE; SEROTONIN SYNDROME; STROKE; SUBPHRENIC HEMATOMA; VASODILATATION;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; HERB-DRUG INTERACTIONS; HUMANS; PHYTOTHERAPY; PLANTS, MEDICINAL; TREATMENT OUTCOME;

EID: 75249084792     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.07.074     Document Type: Review

References (88)

1. Eisenberg D.M., Davis R.B., Ettner S.L., et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 280 (1998) 1569-1575
2. The U.S. Weight Loss and Diet Control Market. 9th edition (2007), Marketdata Enterprises, Tampa, FL
3. Eisenberg D.M., Kessler R.C., Foster C., Norlock F.E., Calkins D.R., and Delbanco T.L. Unconventional medicine in the United States: prevalence, costs, and patterns of use. N Engl J Med 328 (1993) 246-252
4. Vogel J.H., Bolling S.F., Costello R.B., et al. Integrating complementary medicine into cardiovascular medicine: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (Writing Committee to Develop an Expert Consensus Document on Complementary and Integrative Medicine). J Am Coll Cardiol 46 (2005) 184-221
5. Cherniack E.P., Senzel R.S., and Pan C.X. Correlates of use of alternative medicine by the elderly in an urban population. J Altern Complement Med 7 (2001) 277-280
6. Valli G., and Giardina E.G. Benefits, adverse effects and drug interactions of herbal therapies with cardiovascular effects. J Am Coll Cardiol 39 (2002) 1083-1095
7. In: Barnes P.M., Powell-Griner E., McFann K., and Nahin R.L. (Eds). Complementary and Alternative Medicine Use Among Adults, United States, 2002 (2004), U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, Hyattsville, MD
8. Ernst E. Second thoughts about safety of St. John's wort. Lancet 354 (1999) 2014-2016 (erratum in Lancet 2000;355:580)
9. AltCareDex System. Thomson Reuters (HealthCare) Inc. http://www.thomsonhc.com Accessed January 19, 2008
10. Yue Q.Y., Bergquist C., and Gerden B. Safety of St John's wort (Hypericum perforatum). Lancet 355 (2000) 576-577
11. Piscitelli S.C., Burstein A.H., Chaitt D., Alfaro R.M., and Falloon J. Indinavir concentrations and St John's wort. Lancet 355 (2000) 547-548
12. Ernst E. St. John's wort supplements endanger the success of organ transplantation. Arch Surg 137 (2002) 316-319
13. Mai I., Stormer E., Bauer S., Kruger H., Budde K., and Roots I. Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant 18 (2003) 819-822
14. Breidenbach T., Hoffmann M.W., Becker T., Schlitt H., and Klempnauer J. Drug interaction of St John's wort with cyclosporin. Lancet 355 (2000) 1912
15. Sugimoto K, Ohmori M, Tsuruoka S, et al. Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 200;70:518-24.
16. Johne A., Brockmoller J., Bauer S., Maurer A., Langheinrich M., and Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 66 (1999) 338-345
17. Wang Z., Gorski J.C., Hamman M.A., Huang S.M., Lesko L.J., and Hall S.D. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 70 (2001) 317-326
18. Beckman S.E., Sommi R.W., and Switzer J. Consumer use of St. John's wort: a survey on effectiveness, safety, and tolerability. Pharmacotherapy 20 (2000) 568-574
19. Brown T.M. Acute St. John's wort toxicity. Am J Emerg Med 18 (2000) 231-232
20. Lantz M.S., Buchalter E., and Giambanco V. St. John's wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol 12 (1999) 7-10
21. Zou Q.Z., Bi R.G., Li J.M., et al. Effect of motherwort on blood hyperviscosity. Am J Chin Med 17 (1989) 65-70
22. Sung J., Han K.H., Zo J.H., Park H.J., Kim C.H., and Oh B.H. Effects of red ginseng upon vascular endothelial function in patients with essential hypertension. Am J Chin Med 28 (2000) 205-216
23. Siegel R.K. Ginseng abuse syndrome: problems with the panacea. JAMA 241 (1979) 1614-1615
24. Becker B.N., Greene J., Evanson J., Chidsey G., and Stone W.J. Ginseng-induced diuretic resistance. JAMA 276 (1996) 606-607
25. Yuan C.S., Wei G., Dey L., et al. Brief communication: American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled trial. Ann Intern Med 141 (2004) 23-27
26. Sierpina V.S. Integrative health care: complementary and alternative therapies for the whole person (2001), Davis, Philadelphia, PA 134-135
27. Awang D.V. Maternal use of ginseng and neonatal androgenization. JAMA 266 (1991) 363
28. Birks J., and Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev (2007) CD003120
29. Solomon P.R., Adams F., Silver A., Zimmer J., and DeVeaux R. Ginkgo for memory enhancement: a randomized controlled trial. JAMA 288 (2002) 835-840
30. Morris C.A., and Avorn J. Internet marketing of herbal products. JAMA 290 (2003) 1505-1509
31. Gardner C.D., Lawson L.D., Block E., et al. Effect of raw garlic vs commercial garlic supplements on plasma lipid concentrations in adults with moderate hypercholesterolemia: a randomized clinical trial. Arch Intern Med 167 (2007) 346-353
32. Apitz-Castro R., Cabrera S., Cruz M.R., Ledezma E., and Jain M.K. Effects of garlic extract and of three pure components isolated from it on human platelet aggregation, arachidonate metabolism, release reaction and platelet ultrastructure. Thromb Res 32 (1983) 155-169
33. German K., Kumar U., and Blackford H.N. Garlic and the risk of TURP bleeding. Br J Urol 76 (1995) 518
34. Rose K.D., Croissant P.D., Parliament C.F., and Levin M.B. Spontaneous spinal epidural hematoma with associated platelet dysfunction from excessive garlic ingestion: a case report. Neurosurgery 26 (1990) 880-882
35. Bailey D.G., Kreeft J.H., Munoz C., Freeman D.J., and Bend J.R. Grapefruit juice-felodipine interaction: effect of naringin and 6′,7′-dihydroxybergamottin in humans. Clin Pharmacol Ther 64 (1998) 248-256
36. Bailey D.G., Malcolm J., Arnold O., and Spence J.D. Grapefruit juice-drug interactions. Br J Clin Pharmacol 46 (1998) 101-110
37. Gross A.S., Goh Y.D., Addison R.S., and Shenfield G.M. Influence of grapefruit juice on cisapride pharmacokinetics. Clin Pharmacol Ther 65 (1999) 395-401
38. Kivisto K.T., Lilja J.J., Backman J.T., and Neuvonen P.J. Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride. Clin Pharmacol Ther 66 (1999) 448-453
39. Monroe K.R., Murphy S.P., Kolonel L.N., and Pike M.C. Prospective study of grapefruit intake and risk of breast cancer in postmenopausal women: the Multiethnic Cohort Study. Br J Cancer 97 (2007) 440-445
40. Pittler M.H., Guo R., and Ernst E. Hawthorn extract for treating chronic heart failure. Cochrane Database Syst Rev (2008) CD005312
41. Tauchert M. Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure. Am Heart J 143 (2002) 910-915
42. Mashour N.H., Lin G.I., and Frishman W.H. Herbal medicine for the treatment of cardiovascular disease: clinical considerations. Arch Intern Med 158 (1998) 2225-2234
43. Vibes J., Lasserre B., Gleye J., and Declume C. Inhibition of thromboxane A2 biosynthesis in vitro by the main components of Crataegus oxyacantha (Hawthorn) flower heads. Prostaglandins Leukot Essent Fatty Acids 50 (1994) 173-175
44. 1-adrenoceptors in vitro. Prostate 38 (1999) 208-215
45. Bent S., Kane C., Shinohara K., et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 354 (2006) 557-566
46. Bressler R. Herb-drug interactions: interactions between saw palmetto and prescription medications. Geriatrics 60 (2005) 32-34
47. Hamid S., Rojter S., and Vierling J. Protracted cholestatic hepatitis after the use of Prostata. Ann Intern Med 127 (1997) 169-170
48. Yeu E., and Grostern R. Saw palmetto and intraoperative floppy-iris syndrome. J Cataract Refract Surg 33 (2007) 927-928
49. Izzat M.B., Yim A.P., and El-Zufari M.H. A taste of Chinese medicine!. Ann Thorac Surg 66 (1998) 941-942
50. Turner R.B., Bauer R., Woelkart K., Hulsey T.C., and Gangemi J.D. An evaluation of Echinacea angustifolia in experimental rhinovirus infections. N Engl J Med 353 (2005) 341-348
51. Kwan CY, Leung YM, Kwan TK, Daniel EE. Tetrandrine inhibits Ca2+ release-activated Ca2+ channels in vascular endothelial cells. Life Sci 20015;68:841-7.
52. Felix J.P., King V.F., Shevell J.L., et al. Bis (benzylisoquinoline) analogs of tetrandrine block L-type calcium channels: evidence for interaction at the diltiazem-binding site. Biochemistry 31 (1992) 11793-11800
53. Seeff L.B. Herbal hepatotoxicity. Clin Liver Dis 11 (2007) 577-596
54. Bello-Ramirez A.M., and Nava-Ocampo A.A. The local anesthetic activity of Aconitum alkaloids can be explained by their structural properties: a QSAR analysis. Fundam Clin Pharmacol 18 (2004) 157-161
55. Lowe L., Matteucci M.J., and Schneir A.B. Herbal aconite tea and refractory ventricular tachycardia. N Engl J Med 353 (2005) 1532
56. Smith S.W., Shah R.R., Hunt J.L., and Herzog C.A. Bidirectional ventricular tachycardia resulting from herbal aconite poisoning. Ann Emerg Med 45 (2005) 100-101
57. Tam S.W., Worcel M., and Wyllie M. Yohimbine: a clinical review. Pharmacol Ther 91 (2001) 215-243
58. Chen M.Y., Cai J.T., and Du Q. Hepatic veno-occlusive disease associated with the use of Gynura segetum. Eur J Intern Med 18 (2007) 609
59. Dai N., Yu Y.C., Ren T.H., et al. Gynura root induces hepatic veno-occlusive disease: a case report and review of the literature. World J Gastroenterol 13 (2007) 1628-1631
60. Wu X.J., Zhang K., Yu M.Y., Lv H.P., and Zhang G.D. Clinical analysis of four cases of hepatic veno-occlusive disease caused by Gynura segetum (Lour.) Merr. [Chinese]. Zhonghua Gan Zang Bing Za Zhi 15 (2007) 151-153
61. Chitturi S., and Farrell G.C. Hepatotoxic slimming aids and other herbal hepatotoxins. J Gastroenterol Hepatol 23 (2008) 366-373
62. Hoe S.Z., Kamaruddin M.Y., and Lam S.K. Inhibition of angiotensin-converting enzyme activity by a partially purified fraction of Gynura procumbens in spontaneously hypertensive rats. Med Princ Pract 16 (2007) 203-208
63. Mansoor G.A. Herbs and alternative therapies in the hypertension clinic. Am J Hypertens 14 (2001) 971-975
64. Bryer-Ash M., Zehnder J., Angelchik P., and Maisel A. Torsades de pointes precipitated by a Chinese herbal remedy. Am J Cardiol 60 (1987) 1186-1187
65. Eriksson J.W., Carlberg B., and Hillorn V. Life-threatening ventricular tachycardia due to liquorice-induced hypokalaemia. J Intern Med 245 (1999) 307-310
66. Mahady G.B., Low Dog T., Barrett M.L., et al. United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity. Menopause 15 (2008) 628-638
67. Pockaj B.A., Gallagher J.G., Loprinzi C.L., et al. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG trial N01CC1. J Clin Oncol 24 (2006) 2836-2841
68. Top-selling medicinal herbs in the U.S., 1999-2003. In: Park K. (Ed). The World Almanac and Book of Facts, 2005 (2005), World Almanac Books, St. Martin's Press, New York, NY 99
69. Chow E.C., Teo M., Ring J.A., and Chen J.W. Liver failure associated with the use of black cohosh for menopausal symptoms. Med J Aust 188 (2008) 420-422
70. McNamara S.H. FDA regulation of ingredients in dietary supplements after passage of the Dietary Supplement Health and Education Act of 1994: an update. Food Drug Law J 51 (1996) 313-318
71. U.S. Food and Drug Administration. Center for Food Safety and Applied Nutrition. Illnesses and injuries associated with the use of selected dietary supplements. http://www.foodsafety.gov/∼dms/ds-ill.html Accessed April 6, 2009
72. Haller C.A., and Benowitz N.L. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 343 (2000) 1833-1838
73. Bouchard N.C., Howland M.A., Greller H.A., Hoffman R.S., and Nelson L.S. Ischemic stroke associated with use of an ephedra-free dietary supplement containing synephrine. Mayo Clin Proc 80 (2005) 541-545
74. Harris poll shows widespread public ignorance of supplement regulation. http://www.supplementquality.com/news/Harris_survey.html Accessed November 10, 2008
75. Brody J.E. Americans gamble on herbs as medicine. The New York Times. http://query.nytimes.com/gst/fullpage.html?res=9B0DEFDA123BF93AA35751C0A96F958260 Accessed January 6, 2009
76. Saper R.B., Phillips R.S., Sehgal A., et al. Lead, mercury, and arsenic in US- and Indian-manufactured ayurvedic medicines sold via the Internet. JAMA 300 (2008) 915-923
77. Corns C.M. Herbal remedies and clinical biochemistry. Ann Clin Biochem 40 (2003) 489-507
78. Green G.A., Catlin D.H., and Starcevic B. Analysis of over-the-counter dietary supplements. Clin J Sport Med 11 (2001) 254-259
79. Petty H.R., Fernando M., Kindzelskii A.L., et al. Identification of colchicine in placental blood from patients using herbal medicines. Chem Res Toxicol 14 (2001) 1254-1258
80. Debelle F.D., Vanherweghem J.L., and Nortier J.L. Aristolochic acid nephropathy: a worldwide problem. Kidney Int 74 (2008) 158-169
81. Nortier J.L., Martinez M.C., Schmeiser H.H., et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 342 (2000) 1686-1692
82. U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research. Guidance for industry: botanical drug products. http://www.fda.gov/cder/guidance/4592fnl.htm Accessed April 6, 2009
83. U.S. Food and Drug Administration. Overview of Dietary Supplements. http://www.fda.gov/food/DietarySupplements/ConsumerInformation/ucm110417.htm Accessed January 4, 2010
84. Cohen R.J., Ek K., and Pan C.X. Complementary and alternative medicine (CAM) use by older adults: a comparison of self-report and physician chart documentation. J Gerontol A Biol Sci Med Sci 57 (2002) M223-M227
85. Kuo G.M., Hawley S.T., Weiss L.T., Balkrishnan R., and Volk R.J. Factors associated with herbal use among urban multiethnic primary care patients: a cross-sectional survey. BMC Complement Altern Med 4 (2004) 18
86. Department of Health and Human Services, Office of Inspector General. Adverse Event Reporting for Dietary Supplements: An Inadequate Safety Valve. http://www.oig.hhs.gov/oei/reports/oei-01-00-00180.pdf Accessed January 6, 2008
87. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: postmarketing adverse event reporting for nonprescription human drug products marketed without an approved application. http://www.fda.gov/cder/guidance/7950dft.htm Accessed January 6, 2008
88. Institute of Medicine (U.S.). Complementary and alternative medicine in the United States, Committee on the Use of Complementary and Alternative Medicine by the American Public, Board on Health Promotion and Disease Prevention (2005), National Academies Press, Washington, DC